Corbus Pharmaceuticals (NASDAQ:CRBP) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Corbus Pharmaceuticals (NASDAQ:CRBP) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($1.23) EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.03, FiscalAI reports.

Corbus Pharmaceuticals Price Performance

Shares of CRBP stock opened at $11.68 on Thursday. The stock’s fifty day moving average price is $9.77 and its 200 day moving average price is $9.66. Corbus Pharmaceuticals has a 1-year low of $6.72 and a 1-year high of $20.56. The company has a market cap of $207.07 million, a price-to-earnings ratio of -2.03 and a beta of 2.68.

Institutional Investors Weigh In On Corbus Pharmaceuticals

A number of large investors have recently modified their holdings of CRBP. Persistent Asset Partners Ltd acquired a new position in shares of Corbus Pharmaceuticals during the fourth quarter valued at about $54,000. ADAR1 Capital Management LLC purchased a new position in shares of Corbus Pharmaceuticals in the third quarter worth $129,000. Virtu Financial LLC purchased a new stake in shares of Corbus Pharmaceuticals during the fourth quarter valued at $88,000. Barclays PLC increased its position in shares of Corbus Pharmaceuticals by 280.0% in the 4th quarter. Barclays PLC now owns 14,758 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 10,874 shares during the period. Finally, Hudson Bay Capital Management LP purchased a new stake in Corbus Pharmaceuticals in the fourth quarter valued at approximately $139,000. Hedge funds and other institutional investors own 64.64% of the company’s stock.

Key Headlines Impacting Corbus Pharmaceuticals

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: Corbus appointed pharma industry veteran Brent Pfeiffenberger, PharmD, MBA, to its Board of Directors, which could strengthen governance and strategic execution as the company advances its oncology and obesity pipeline. Article Title
• Positive Sentiment: HC Wainwright and Lifesci Capital both nudged longer-term earnings estimates higher in several periods, suggesting slightly improved analyst expectations for Corbus’ future profitability profile.
• Positive Sentiment: Guggenheim reaffirmed a buy rating and Oppenheimer maintained an outperform rating, with both firms still seeing substantial upside from the current share price despite trimming one price target.
• Neutral Sentiment: Corbus said CEO Yuval Cohen will present at the RBC Capital Markets Global Healthcare Conference and attend meetings at the Jefferies Global Healthcare Conference, which keeps the company visible to investors but does not by itself change fundamentals. Article Title
• Negative Sentiment: Despite the positive analyst tone, Corbus remains unprofitable and forecast EPS is still deeply negative across 2026–2029, which can limit enthusiasm and help explain why the stock has been weak overall.

Wall Street Analysts Forecast Growth

CRBP has been the subject of several recent research reports. Guggenheim reissued a “buy” rating and issued a $45.00 price target on shares of Corbus Pharmaceuticals in a research report on Wednesday. Oppenheimer dropped their price objective on Corbus Pharmaceuticals from $57.00 to $54.00 and set an “outperform” rating on the stock in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a report on Monday, April 20th. Jefferies Financial Group decreased their price target on shares of Corbus Pharmaceuticals from $36.00 to $33.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Wall Street Zen raised shares of Corbus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.33.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.